Inspira Technologies Oxy B.H.N. Ltd. (IINN)
NASDAQ: IINN · Real-Time Price · USD
1.320
+0.040 (3.13%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure.

Its lead product is the INSPIRA augmented respiration technology (Gen 2) device, a life support designed to provide Adaptive Blood Oxygenation that to elevate and stabilize declining oxygen saturation levels.

The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N.

Ltd. in July 2020. Inspira Technologies Oxy B.H.N.

Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.

Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. logo
Country Israel
Founded 2018
IPO Date Jul 14, 2021
Industry Medical Devices
Sector Healthcare
Employees 42
CEO Dagi Ben-Noon

Contact Details

Address:
2 Ha-Tidhar Street
Ra'anana, 4366504
Israel
Phone 972 4 6230333
Website inspira-technologies.com

Stock Details

Ticker Symbol IINN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.51
CIK Code 0001837493
CUSIP Number M53637100
ISIN Number IL0011715781
SIC Code 3841

Key Executives

Name Position
Dagi Shahar Ben-Noon Co-Founder, Chief Executive Officer and Director
Joe Hayon Co-Founder, President and Director
Yafit Tehila Chief Financial Officer
Avi Shabtai Chief Operating Officer and Vice President of Research and Development
Daniella Yeheskely-Hayon Ph.D. Chief Technology Officer
Meshira Greenberg Administrative Manager
Adi Shmueli Director of Marketing

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 6-K Report of foreign issuer
Oct 24, 2024 6-K Report of foreign issuer
Oct 9, 2024 6-K Report of foreign issuer
Sep 26, 2024 EFFECT Notice of Effectiveness
Sep 13, 2024 6-K Report of foreign issuer
Aug 29, 2024 POS AM Post-Effective amendments for registration statement
Aug 28, 2024 6-K Report of foreign issuer
Aug 26, 2024 144 Filing
Aug 22, 2024 6-K Report of foreign issuer